Abstract
This review describes the role of neprilysin (also known as neutral endopeptidase or enkephalinase) in the degradation of natriuretic and other vasoactive peptides, including bradykinin and adrenomedullin. The initial development of neprilysin inhibitors, then angiotensin converting enzyme‐neprilysin inhibitors and, most recently, the angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 (sacubitril valsartan) as an extension of the nurohumoral basis for the treatment of heart failure is also summarised. Finally, the implications of the compelling benefits of LCZ696 compared with enalapril in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF) is discussed.
Keywords
NeprilysinSacubitrilHeart failureMedicineValsartanEnalaprilBradykininInternal medicineCardiologyAngiotensin-converting enzymePharmacologyEjection fractionReceptorBlood pressureEnzymeChemistry
Affiliated Institutions
Related Publications
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)
Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single mol...
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
Aims Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone sys...
Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition
Angiotensin-converting enzyme and neutral endopeptidase (EC 3.4.24.11; neprilysin) are metallopeptidases present on the endothelium that metabolize bradykinin. Inhibitors of ang...
Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGM‐HF</scp>)
Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM‐HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global ...
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Publication Info
- Year
- 2015
- Type
- review
- Volume
- 17
- Issue
- 3
- Pages
- 242-247
- Citations
- 121
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
121
OpenAlex
Cite This
John J.V. McMurray
(2015).
Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
European Journal of Heart Failure
, 17
(3)
, 242-247.
https://doi.org/10.1002/ejhf.250
Identifiers
- DOI
- 10.1002/ejhf.250